From Blood Tests to Better Decisions: GUIDE.MRD Advances the Future of Personalised Cancer Care
GUIDE.MRD partners gathered in Switzerland to advance liquid biopsy research in colorectal, pancreatic, and lung cancers. The project aims to detec...
New Targeted Pill Shows Promise for Advanced Pancreatic Cancer
A new targeted treatment for advanced pancreatic cancer has shown encouraging early results in a major clinical trial. The experimental pill, darax...
Patients at the Heart of Innovation: DiCE at the GUIDE.MRD Annual Assembly in Nice
DiCE joined the GUIDE.MRD General Assembly in Nice, where our team co-led a powerful Patient Advisory Board session. Patient representatives highli...
The POLAR Promise: Groundbreaking Survival Gains for Targeted Pancreatic Cancer Patients in Phase II Trial
Phase II trial of Pembrolizumab Immunotherapy and Olaparib (POLAR) trial new data presented at the European Society for Medical Oncology (ESMO) 202...
GUIDE.MRD Consortium Holds Productive 2nd Annual General Assembly in Hamburg
The GUIDE.MRD consortium’s 2nd annual general assembly in Hamburg discussed progress and challenges across all work packages, with over 30 pa...
EMA Approves New First-line Treatment Option for Metastatic Pancreatic Cancer
Irinotecan hydrochloride trihydrate (Onivyde pegylated liposomal) was approved in March 2024 by the European Medicines Agency (EMA). Indications: N...
“DIGESTIVE CANCER – CURRENT AND FUTURE APPROACHES FOCUSED ON PREVENTION” Highlights the Importance of Awareness and Prevention
In summary, the event was a crucial opportunity to bring together experts and the community at large to address the challenges of digestive cancer,...
Gemcitabine Plus Paclitaxel vs Gemcitabine Alone after FOLFIRINOX in Metastatic Pancreatic Cancer
GEMPAX was an open-label (both researchers and patients know which treatment is being administered), randomised (randomly assigns participants in...
F2F Consortium Meeting in Madrid
The GUIDE.MRD (Guiding multi-modal therapies against MRD by liquid biopsies) consortium partners met for the first face-to-face annual meeting...
Predictive Values of Blood-based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer
Presently, no widely recognised or established biomarkers are specifically designed to predict the effectiveness of FOLFIRINOX/FOLFOX (chemotherape...